FDA reviewers proposed implementing a REMS to address loss-of-consciousness events associated with brexanolone (SAGE-547) from Sage Therapeutics Inc. (NASDAQ:SAGE) to treat postpartum depression (PPD), according to a briefing document issued ahead of a joint advisory committee meeting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,